Global Interventional Oncology Devices Market Targets Growth to $3.25 Billion by 2028
March 26, 2024 18:10 ET
|
Research and Markets
Dublin, March 26, 2024 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Market Expansion Driven by...
American Medical Association Issues New CPT Code for Use of Seno Medical’s Opto-acoustic Technology in Breast Cancer Diagnosis
February 13, 2024 10:00 ET
|
Seno Medical
San Antonio, TX, Feb. 13, 2024 (GLOBE NEWSWIRE) -- The American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT*) code for the use of Imagio® (OA/US)...
Seno Medical’s SenoGram® Decision Support Tool Named Winner in 2023 Artificial Intelligence Excellence Awards
March 23, 2023 09:30 ET
|
Seno Medical
San Antonio, TX, March 23, 2023 (GLOBE NEWSWIRE) -- The Artificial Intelligence Excellence Awards program has selected Seno Medical’s AI platform, SenoGram® — exclusively available in conjunction...
New book shares one woman’s experiences, insights and perspectives gleaned from navigating a genetically driven breast cancer diagnosis
November 18, 2020 02:48 ET
|
Balboa Press
SHAKER HEIGHTS, Ohio, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Penny Casselman marks her publishing debut with the release of “How To Get A Free Boob Job” (published by Balboa Press). With sprinkles of...
Atossa Genetics' National Reference Laboratory for Breast Health Receives CLIA Certification
March 05, 2012 09:48 ET
|
Atossa Genetics, Inc.
SEATTLE, WA--(Marketwire - Mar 5, 2012) - Atossa Genetics, Inc., a private healthcare company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can...